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ABSTRACT 22 
 23 
Background 24 
Prolonged acute hospital stays are a major problem for older people and for health services.  Failure 25 
to effectively manage psychological and social aspects of illness is an important cause of prolonged 26 
hospital stays.  Proactive Psychological Medicine (PPM) is a new way of providing psychiatry services 27 
to medical wards which is proactive, focussed, intensive and integrated with medical care.  A major 28 
aim of PPM is to reduce the time older people spend in hospital because of unmanaged 29 
psychological and social problems.  The HOME Study will test the effectiveness and cost-30 
effectiveness of PPM. 31 
 32 
Methods / design 33 
A two-arm parallel group randomised controlled superiority trial, with a linked health economic 34 
analysis and an embedded process evaluation, will be conducted at three sites.  A total of 3,588 35 
participants will be recruited and randomised to usual care or usual care plus PPM.  The primary 36 
outcome is the number of days spent as an inpatient in a general hospital in the month (30 days) 37 
post-randomisation.  Secondary outcomes (measured at one and three months) include quality of 38 
life, independent functioning, symptoms of anxiety and depression, and experience of hospital stay. 39 
 40 
Discussion 41 
The trial has been designed to produce findings that are generalisable to all older medical inpatients 42 
(including those with cognitive impairment).  It will provide information on the effectiveness and 43 
cost-effectiveness of PPM that we hope will be of value to patients, clinicians, managers and service 44 
planners. 45 
 46 
Trial registration 47 
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ISRCTN 86120296. http://www.isrctn.com/ISRCTN86120296 Registered 03/01/2018 48 
 49 
 50 
KEYWORDS 51 
Randomised controlled trial, protocol, psychological medicine, liaison psychiatry, multi-morbidity. 52 
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BACKGROUND  54 
Prolonged acute hospital stays are a major problem for older people and for health services.  In the 55 
UK, National Health Service (NHS) acute hospitals have more than two million unplanned admissions 56 
of people aged 65 and older every year.  The greater length of stay of older patients means that 57 
these admissions account for most (70%) of the available emergency bed days [1].  Excessive time in 58 
hospital is bad for patients: it leads to hospital-acquired illnesses, demoralisation and loss of 59 
independence after discharge [2].  It is also bad for the hospitals as it reduces the availability of beds 60 
for other people and increases costs.  For these reasons health services are seeking to reduce the 61 
time older people spend in hospital and to improve out of hospital care.  A recent review of 62 
organisational interventions to reduce length of stay in hospital found that, whilst many of the 63 
initiatives which aimed to achieve this showed promise, none were of proven effectiveness [3].  64 
 65 
The reasons for prolonged hospital stays include not only the complexity of older patients’ medical 66 
problems, but also inadequately managed psychological and social problems.  The psychological 67 
problems include psychiatric illnesses such as delirium, dementia, and depression as well as minor 68 
cognitive impairment or anxiety, all of which may slow patients’ discharge from hospital [4, 5].  The 69 
social problems include delays in organising post-discharge care arrangements, family members’ 70 
expectations or concerns about where the patient will go when they leave hospital, and 71 
miscommunications and conflicts about discharge planning within the clinical team.  Failure to 72 
effectively manage these problems is well documented [6].   73 
 74 
These psychological and social problems are usually addressed by providing a type of psychiatric 75 
care to medical wards called liaison psychiatry.   Liaison psychiatry services consequently have the 76 
potential to reduce the time that older people spend in hospital.  However, they currently have 77 
limited ability to do this because: (a) they operate using a referral model and therefore only see the 78 
small minority of patients identified as having obvious psychiatric problems by medical teams; (b) 79 
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they do not have a consistent focus on reducing time in hospital; (c) their contributions to the care 80 
of these patients is typically limited to consultations and advice; (d) they have limited integration 81 
with the patient’s clinical team.  Perhaps not surprisingly, the current evidence for the effectiveness 82 
and cost-effectiveness of such services is very limited [7]. 83 
 84 
We have developed a new service model called Proactive Psychological Medicine (PPM) that aims to 85 
be more effective in reducing time in hospital.  The new model aims to address the limitations of the 86 
current approach: (a) it is proactive in seeing all admitted patients (building on the experience of a 87 
proactive psychiatric consultation service initiated in Yale Newhaven hospital in the USA [8, 9]); (b) it 88 
takes a broad biopsychosocial approach focussing on facilitating prompt discharge; (c) it provides an 89 
intensive contribution to care with comprehensive consultant assessment and daily follow-up; (d) it 90 
is integrated, with PPM clinicians working as members of the patient’s extended medical team.  We 91 
have piloted this new PPM service model and found it to be both feasible and acceptable in an NHS 92 
general hospital setting.   93 
 94 
The HOME Study aims to determine whether adding PPM to usual care reduces the time spent by 95 
older patients in acute hospital wards in the month (30 days) after randomisation (primary 96 
outcome), when compared with usual care alone.  A number of secondary outcomes, including 97 
patients’ views of their length of time in hospital and quality of life will also be evaluated.  We will 98 
also determine the cost-effectiveness of adding PPM to usual care. 99 
 100 
  101 
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METHODS  102 
Design  103 
A pragmatic multicentre two-arm parallel group randomised controlled superiority trial with a linked 104 
health economic analysis and an embedded process evaluation. 105 
 106 
Patients 107 
3,588 patients will be recruited from the acute wards (not emergency departments) of Oxford 108 
University Hospitals NHS Foundation Trust, Royal Devon and Exeter NHS Foundation Trust and 109 
Cambridge University Hospitals NHS Foundation Trust.  We aim to recruit from at least four wards 110 
per hospital over at least 18 months. 111 
 112 
To be included in the trial patients must: 113 
 Be aged 65 or older. 114 
 Be an inpatient in an acute ward where trial recruitment is taking place.  115 
 Have been admitted non-electively (i.e. their hospital admission was unplanned). 116 
 Be expected by their clinical team to remain an inpatient for at least two days from the time of 117 
trial enrolment.  118 
 Be able to give informed consent or if unable to give consent, a consultee advises that trial 119 
participation is appropriate. 120 
 121 
Patients will be excluded if at the time of enrolment: 122 
 They are moribund – defined in this trial as when the clinicians caring for a patient estimate that 123 
they are likely to die before discharge from hospital. 124 
 Their participation in the trial is judged to be clinically or practically inappropriate (e.g. the 125 
patient is not from the local area served by the hospital). 126 
 They have already been enrolled in the trial. 127 
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 They have already been referred to the usual care liaison psychiatry team. 128 
 They have already been a general hospital inpatient continuously for one week. 129 
 They do not read or speak English. 130 
 131 
Patient identification and enrolment 132 
Screening will be used to identify potential participants, in order to obtain a representative sample 133 
of the relevant population, and to give all potentially eligible patients the opportunity to participate.  134 
Researchers will screen all patients admitted to the participating wards during the trial period for 135 
eligibility.  This will be done by accessing their medical records and also obtaining relevant 136 
information from clinicians.  Patients identified as eligible by this process will be offered both verbal 137 
and written information about the trial.  They will be given a full explanation of both of the 138 
treatment allocations, and the procedures for randomisation and outcome data collection.  Written 139 
informed consent will then be obtained for trial participation (procedures for patients who lack 140 
capacity are described below).  At all stages the research team will endeavour to record reasons for 141 
non-participation.   142 
 143 
Recruitment of patients who lack capacity 144 
‘Capacity’ refers to a patient’s ability to make the decision whether to participate in The HOME 145 
Study.  Recruitment of patients who lack capacity will be in accordance with the Mental Capacity Act 146 
2005 with specific reference to sections 30 to 34.  A personal consultee (a family member, carer or 147 
friend; an attorney under a Lasting Power of Attorney; or a court appointed deputy provided that 148 
they had a relationship with, or personal knowledge of, the person lacking capacity before their 149 
appointment as deputy) will be identified for the patient where possible.  The personal consultee 150 
will be asked to advise on the patient’s likely thoughts and feelings about the research and whether 151 
they should be enrolled in the trial.  If a personal consultee cannot be identified or cannot be 152 
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contacted within 24 hours, a nominated consultee will be approached for advice regarding the 153 
patient’s participation in the trial. 154 
 155 
Baseline data 156 
The following baseline data will be collected: 157 
 Name of hospital and ward at the time of recruitment 158 
 NHS and hospital numbers (to allow matching with routine data). 159 
 Date of birth. 160 
 Sex. 161 
 Ethnicity. 162 
 Relationship status (whether the patient has a partner or spouse). 163 
 Usual place of residence (private home, care home etc.). 164 
 Postcode (to calculate deprivation index & urban/rural residence). 165 
 Whether the participant lives alone. 166 
 Employment status. 167 
 Reason for hospital admission (presenting complaint or working diagnosis). 168 
 Diagnoses (medical and psychiatric) recorded on admission. 169 
 Medication prescribed. 170 
 Date of hospital admission. 171 
 Date of admission to specified acute ward. 172 
 Days in hospital prior to enrolment. 173 
 Cognitive function, measured by the Montreal Cognitive Assessment-Telephone version [10]. 174 
 Independent functioning, measured by the Barthel Index of Activities of Daily Living [11]. 175 
 Health-related quality of life, measured by the EQ-5D-5L [12]. 176 
 Symptoms of anxiety and depression, measured by the Patient Health Questionnaire-4 [13]. 177 
 Overall quality of life, measured by a trial-specific item. 178 
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 Secondary healthcare use (including number of admissions to hospital) in the year prior to 179 
randomisation. 180 
 181 
Questionnaire data will be collected from the participant using a brief face-to-face interview as soon 182 
as possible prior to randomisation.  Some participants will be unable to give reliable data, even with 183 
help.  In this instance, data will be collected from proxies wherever possible.   184 
 185 
Randomisation 186 
A database software algorithm, designed by the trial statistician, will allocate participants to usual 187 
care plus PPM or usual care alone in a 1:1 ratio with stratification by putative prognostic variables: 188 
hospital, sex and age (65-74, 75-84, ≥85). The algorithm is based on Stata’s “ralloc” command and 189 
utilises random permuted blocks of variable size.  The required random seed was selected by the 190 
Oxford Clinical Trials Research Unit, which will implement the randomisation system.  The 191 
participant’s details will be entered into the database via a secure website.   192 
 193 
Blinding 194 
Trial statisticians and research staff who collect outcome data will be blinded to participants’ 195 
allocated interventions.  HOME Study researchers who recruit participants will carry out the 196 
randomisation procedure described above. They will inform participants of their treatment 197 
allocation, and will inform the PPM teams about participants who have been allocated to usual care 198 
plus PPM.  Recruiting researchers, participants and clinicians will not be blinded to treatment 199 
allocation.   200 
 201 
Trial treatment – intervention (usual care supplemented with Proactive Psychological Medicine) 202 
Proactive Psychological Medicine (PPM) has four main components: 203 
 204 
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(a) Early proactive biopsychosocial assessment of newly admitted patients using a biopsychosocial 205 
approach to identify all problems, including psychiatric illness. 206 
(b) The creation of a systematic management plan to address those problems that pose potential 207 
barriers to prompt discharge. 208 
(c) Implementation of the management plan with daily progress reviews. 209 
(d) Integrated working with ward teams (doctors, nurses, allied health professionals and social care 210 
professionals) and out of hospital services to ensure that the management plan is implemented. 211 
 212 
PPM will be delivered at each trial site by a specially trained consultant in psychological 213 
medicine/liaison psychiatry and an assisting clinician who will work as additional members of the 214 
patient’s medical team (the assisting clinician may be a junior doctor, a nurse or an allied health 215 
professional with experience of working in psychological medicine/liaison psychiatry).  Each of these 216 
clinicians will have a backup to cover leave.  In order to ensure fidelity to the service model, the PPM 217 
clinicians will: (a) deliver PPM according to a service manual; (b) use a PPM checklist for each 218 
patient; (c) be required to pass quality assessments prior to treating trial participants; (d) participate 219 
in weekly joint supervision by video-conference; (e) be subject to regular quality assurance checks 220 
throughout the trial. 221 
 222 
Trial treatment – comparison (usual care) 223 
This is a pragmatic trial and the comparator arm is usual care.  Participants allocated to this arm will 224 
receive usual medical care, including the option for the patient’s medical team to request a 225 
consultation from the hospital’s usual liaison psychiatry team.  Referrals to usual care liaison 226 
psychiatry will be recorded (see process evaluation below). 227 
 228 
Primary outcome 229 
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The primary outcome is the number of days spent as an inpatient in a general hospital in the month 230 
(30 days) post-randomisation.   231 
 232 
Secondary outcomes 233 
The following secondary outcomes will be assessed: 234 
 Cognitive function, measured by the Montreal Cognitive Assessment-Telephone version at one 235 
and three months post-randomisation [10]. 236 
 Independent functioning, measured by the Barthel Index of Activities of Daily Living at one and 237 
three months post-randomisation [11]. 238 
 Health-related quality of life, measured by the EQ-5D-5L at one and three months post-239 
randomisation [12]. 240 
 Symptoms of anxiety and depression, each measured by the relevant two items of the Patient 241 
Health Questionnaire-4 at one and three months post-randomisation [13]. 242 
 Overall quality of life, measured by a trial-specific item (0 to 10 scale) at one and three months 243 
post-randomisation. 244 
 Patient’s experience of hospital stay, measured by a trial-specific item (0 to 10 scale) at one 245 
month post-randomisation. 246 
 Patient’s view on the length of their hospital stay, measured by a trial-specific item at one month 247 
post-randomisation. 248 
 Discharge destination. 249 
 Secondary healthcare use in the year post-randomisation (including total length of index 250 
admission, number of readmissions, number of days in hospital). 251 
 Death in the year post-randomisation. 252 
 253 
Measures of cost and health-related quality of life 254 
The following economic outcome measures will be assessed: 255 
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 Quality adjusted life years (QALYs), estimated using the EQ-5D-5L measure. 256 
 Cost of secondary healthcare use. 257 
 Cost of PLP/PPM. 258 
 259 
Outcome data collection 260 
Data describing the participant’s hospital stay, their discharge destination, subsequent hospital 261 
admissions, secondary healthcare use and mortality data will be obtained from national datasets of 262 
routinely collected clinical data and from local hospital records and datasets.  At one month (30 263 
days) and three months (90 days) post-randomisation, a member of the research team will contact 264 
the participant (or an appropriate proxy) to administer the questionnaires by telephone or face-to-265 
face.  The time windows for data collection are as follows: one month data will be collected between 266 
day 30 and day 75 post-randomisation (inclusive of these dates) and three month data will be 267 
collected between day 90 and day 135 post-randomisation (inclusive of these dates). 268 
 269 
Active measures will be taken to minimise missing data.  These will include:  270 
 The use of routinely collected clinical data to provide the primary outcome. 271 
 Obtaining full contact details from participants. 272 
 Obtaining a back-up ‘best contact’ address (i.e. contact details of a friend/relative nominated by 273 
the participant). 274 
 Recording participants’ discharge destination from hospital. 275 
 Collection of data from proxies where participants are unable to give reliable data. 276 
 Reminder telephone calls and letters. 277 
 Checks with the patient’s GP to determine if they are alive and/or have moved address.   278 
 279 
Data management 280 
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To ensure that all data are reliable and have been processed correctly, standard operating 281 
procedures will be implemented at each stage of the data handling process and all electronic data 282 
collated will be checked for accuracy as follows: 100% check on the primary outcome measure and a 283 
random minimum 10% sample check on all other outcome measures. 284 
 285 
Personal data will be stored separately from research data, once transferred to the main trial office.  286 
All documents will be stored securely and only accessible by trial staff and authorised personnel. 287 
Data will be anonymised as soon as it is practical to do so.   288 
 289 
Safety 290 
The Serious Adverse Events (SAEs) which will be recorded and reported in this trial are deaths by any 291 
cause in the 30 days post-randomisation.  Re-hospitalisations, life-threatening illness and significant 292 
disability are to be expected in this group of patients and will not, therefore, be recorded as SAEs. 293 
 294 
Sample size 295 
A total of 3,588 participants is required to detect a reduction of 1 day (from 9 to 8 days, standard 296 
deviation 9) in mean number of days in hospital with 90% power at the 5% significance level, a two-297 
tailed test and allowing for 5% loss to follow-up.   298 
 299 
Statistical analyses  300 
A single main analysis will be performed at the end of the trial when all outcome data have been 301 
collected.  A detailed Statistical Analysis Plan will be developed prior to closure of the trial database 302 
and prior to the un-blinding of the treatment allocations.  Primary analysis of the primary and 303 
secondary outcomes will follow the intention to treat principle (i.e. the participants will remain in 304 
the group they were randomised to and not analysed according to the interventions actually 305 
received).  For the primary outcome (number of days spent in hospital in the 30 days post 306 
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randomisation), the difference between the means with a 95% confidence interval will be reported.  307 
This will be obtained from a linear regression model.  This model will include: (a) centre (Cambridge, 308 
Exeter, Oxford) by treatment interaction terms; (b) stratification factors (hospital, gender and age: 309 
which will be treated as continuous in the analysis model, but in three categories for stratification) 310 
as fixed effects; and (c) wards as either fixed or random effects (the final choice being dependent on 311 
the number of wards included).  The primary outcome will be a weighted mean of the three centre-312 
specific treatment effects, with weights proportional to the number of people randomised at each 313 
centre. In the event of substantial departure from normality assumptions non-parametric bootstrap 314 
(bias corrected and accelerated, 2000 replications, with allowance for stratification) methodology 315 
will be used to construct the confidence interval.  Secondary continuous outcomes will be analysed 316 
in an analogous fashion to the primary outcome.  For binary outcomes risk ratios and risk differences 317 
will be estimated.  These will be obtained from generalised linear models (with adjustment for 318 
stratification factors).  Further secondary analysis will consider time until leaving hospital as a 319 
survival time, with Cox models used to estimate hazard ratios.  320 
 321 
Economic evaluation 322 
Cost-effectiveness will be assessed from the perspective of the NHS with outcomes expressed in 323 
terms of quality-adjusted life-years (QALYs), in line with current UK guidance for economic 324 
evaluations [14].  In the case of one form of management being more costly and more effective, 325 
incremental cost-effectiveness ratios will be presented for the alternative options and compared 326 
with appropriate cost-effectiveness ‘thresholds’ for the NHS; these will also be presented as net 327 
health effects with ‘thresholds’ representing the forgone opportunities to improve other patients’ 328 
health (opportunity costs) [15].  For the base case, cost-effectiveness will be assessed over the one 329 
year trial period. The within-trial analyses will be conducted using appropriate statistical techniques 330 
to control for any baseline differences in covariates between patient groups and for issues with non-331 
normality of cost and outcome data [16].  Missing data will be handled using imputation with 332 
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chained equations [17]. Decision uncertainty resulting from the estimation of the within-trial 333 
analysis cost-effectiveness will be presented using cost-effectiveness acceptability curves [18]. The 334 
consequences of decision uncertainty and the potential value of additional research will be assessed 335 
using value of information analysis [19].  Scenario and sensitivity analyses will also be undertaken to 336 
examine the impact of key assumptions and uncertainties.  If important differences in costs and/or 337 
outcomes between the management strategies are found over the trial period and would be 338 
expected to persist over the longer term, extrapolation of the trial results will be conducted.  This 339 
will involve the development of a decision analytic model which will synthesise evidence from the 340 
trial with other external sources to estimate the costs and QALYs over patients’ lifetime [19, 20].   341 
 342 
Process evaluation 343 
An embedded process evaluation will be used to describe: the relevant care received by participants 344 
during their hospital stay; patients’, carers’ and healthcare professionals’ experience of PPM; and 345 
the context in which PPM is delivered during the trial.  Data will be collected from participants’ 346 
medical records and through qualitative interviews with participants (a subgroup of the total 347 
sample), carers and healthcare professionals who deliver PPM or work on the relevant hospital 348 
wards.   349 
 350 
Trial management and monitoring 351 
The Trial Management Group (TMG) will be responsible for the day-to-day running of the trial, 352 
including recruitment monitoring, outcome data collection, and communication of protocol changes 353 
to the relevant parties.  The trial will be overseen by an independent Trial Steering Committee (TSC), 354 
which will meet at least annually to consider and address strategic issues.  A Data Monitoring 355 
Committee (DMC), members of which will act independently of the TSC, TMG and Funder, will 356 
monitor data and make recommendations to the TSC on whether there are any ethical or safety 357 
reasons why the trial should not continue.  The DMC will monitor the occurrence of serious adverse 358 
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events (SAEs) and suspected unexpected serious adverse reactions (SUSARs), i.e. serious adverse 359 
events that are likely to be due to the implementation of PPM.  The DMC will focus particularly on 360 
the number of participant deaths that occur within 30 days of trial enrolment.  Interim analyses of 361 
the primary outcome data will not be undertaken because these require data that will not be 362 
available during the relatively short recruitment period.  There are therefore no statistical stopping 363 
rules for this trial related to the primary outcome and the DMC will recommend stopping only on 364 
safety grounds.  Audits appropriate to the trial will be planned and conducted by the Oxford Clinical 365 
Trials Research Unit. 366 
 367 
Dissemination 368 
The results of the trial will be analysed and published as soon as possible.  The results will be 369 
reported in the first instance to the funding body and study collaborators.  A writing committee, 370 
chaired by the Chief Investigator, will be constituted with the aim of prompt publication of trial 371 
reports in high impact journals.  A lay summary of the trial findings will be made available on the trial 372 
website. 373 
  374 
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DISCUSSION 375 
This trial addresses an important and topical question: does addressing older medical patients’ 376 
psychological and social problems with a new psychiatry service model reduce the time they spend 377 
in acute hospitals and does it produce better patient outcomes?  378 
 379 
The trial has been designed with the aim of providing a clear answer to this question.  In order to 380 
ensure that the findings are robust we will: (a) recruit a large sample in order to detect a clinically 381 
meaningful effect if one exists; (b) recruit a representative sample by using screening to identify 382 
potential participants, including patients with cognitive impairment and recruiting in hospitals that 383 
together serve both urban and rural populations of varying socioeconomic status; (c) deliver the 384 
experimental intervention with adequate quality assurance whilst taking steps to minimise 385 
contamination of usual care; (d) evaluate effectiveness using a primary outcome that is not 386 
susceptible to reporting bias or missing data, supplemented with patient-reported secondary 387 
outcomes; (e) conduct an embedded process evaluation so that if PPM is found to be effective we 388 
have information on how best to implement it, and if it is found to be ineffective and we have 389 
information on the possible reasons for this finding; and (f) undertake a cost-effectiveness analysis 390 
to establish whether PPM can be considered a good use of resources compared to other NHS 391 
activities. 392 
 393 
A major consideration in the design of this trial was whether to use cluster or individual 394 
randomisation.  Cluster randomisation was considered on the basis that PPM teams work in an 395 
integrated way with patients’ other hospital clinicians and there is a potential for usual care to be 396 
contaminated by elements of PPM.  However, we concluded that individual randomisation was most 397 
suitable because: (a) PPM is designed to affect patient care at the individual level and delivered with 398 
this in mind (e.g. PPM teams work in collaboration with other clinical staff but do not provide formal 399 
education or seek to change the way a ward operates); (b) contamination is likely to be minimal 400 
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because PPM is so dissimilar to traditional liaison psychiatry consultations that participants allocated 401 
to usual care would only receive it if a major change were to occur in the configuration of existing 402 
services; (c) there is no clearly appropriate natural cluster (e.g. ward) because hospitals are 403 
organised differently: some have ward-based medical teams, whereas others have teams that are 404 
responsible for patients admitted during the course of a given timeframe (‘on-take’ teams); and (d) if 405 
we randomised wards these would be ‘open clusters’ - the ward’s allocation to PPM or usual care 406 
would be known to clinical staff and might influence which patients they admitted to each ward.  We 407 
have therefore elected to use individual randomisation and to take precautions to limit 408 
contamination including ensuring that ward teams understand the need to adhere to randomised 409 
patient allocation and separation of PPM teams from those delivering usual care liaison psychiatry 410 
services. 411 
 412 
We also carefully considered which measures should be used.  The primary outcome uses routinely 413 
collected data and therefore neither places a burden on participants, nor depends on their ability to 414 
respond to questions from a researcher.  We conducted pilot work to ensure the secondary outcome 415 
measures would be suitable for unwell older people who may have cognitive impairment.  They 416 
were chosen for their suitability to be delivered by telephone or face-to-face, and to proxies when 417 
participants are unable to provide data.     418 
 419 
The trial aims to provide robust information on the role of psychiatry in the care of elderly medical 420 
inpatients that we hope will be of value to patients, clinicians, managers and service planners. 421 
 422 
TRIAL STATUS 423 
Recruitment commenced 2nd May 2018.  Recruitment is expected to be completed on 31st 424 
December 2019.  The current protocol version is 6.0, 09/11/2018. 425 
19 
 
 426 
DECLARATIONS 427 
Sponsorship and funding 428 
The trial sponsor is the University of Oxford. The trial is funded by the National Institute for Health 429 
Research – Health Services Delivery Research Programme (15/11/16).  Neither the sponsor nor the 430 
funder have had or will have any involvement in the study design; collection, management, analysis, 431 
and interpretation of data; writing of the report; and the decision to submit the report for 432 
publication.  There are no contractual agreements that limit the investigators’ access to the final trial 433 
dataset.  434 
 435 
Ethics approval and consent to participate 436 
The trial was reviewed and given ethical approval, which applies to all sites, by the South Central-437 
Oxford C Research Ethics Committee (17/SC/0497).  Additional site-level regulatory agreements have 438 
also been obtained prior to recruitment commencing.  The trial will be conducted in accordance with 439 
Good Clinical Practice (GCP) guidelines, the General Data Protection Regulation, the Research 440 
Governance Framework and the Mental Capacity Act 2005.  All participants (or their consultees) will 441 
receive oral and written information about the trial and must give their informed consent (or 442 
agreement if a consultee) before enrolment.  Participants are free to withdraw at any time.  The 443 
protocol has been written in accordance with the Standard Protocol Items: Recommendation for 444 
Interventional Trials (SPIRIT) checklist. 445 
 446 
Consent for publication 447 
Not applicable. 448 
 449 
Availability of data and material 450 
Not applicable. 451 
20 
 
 452 
Competing interests 453 
JW, KB, MT, MvN, CF, NM, SW, MS and MS have no competing interests. 454 
 455 
Authors' contributions 456 
JW contributed to the trial design and drafted the manuscript. KB contributed to the trial design. MT 457 
contributed to the trial design. MvN contributed to the trial design. CF contributed to the trial design 458 
and wrote the statistical analysis. NM contributed to the trial design and statistical analysis planning.  459 
SW contributed to the trial design and wrote the economic evaluation plan. MS contributed to the 460 
trial design and oversaw the economic evaluation planning. IRW contributed to the trial design and 461 
statistical analysis planning.  MS conceived of the study and contributed to the trial design and 462 
manuscript writing.  All authors read and approved the final manuscript. 463 
 464 
Trial committees 465 
Trial Management Group: Michael Sharpe, Jane Walker, Chris Frost, Nicholas Magill, Katy Burke, 466 
Mark Toynbee, Maike van Niekerk, Chris Dickens, Nicola Walker, Annabel Price, Stephen Kelleher, 467 
Gloria Calderon, Vicki Barber. 468 
Trial Steering Committee: Amanda Ramirez, Peter White, Hywel Jones, Chris Griffiths, Paul McCrone, 469 
Aileen Clarke, Mark Mullee, Thomas Jackson. 470 
Data Monitoring Committee: Matthew Hotopf, Sabine Landau, Tomas Welsh.  471 
21 
 
REFERENCES 472 
 473 
1. Imison C, Thompson, J. & Poteliakhoff: Older people and emergency bed use. Exploring 474 
variation. London: The King's Fund; 2012. 475 
2. Tadd W, Hillman A, Calnan S, Calnan M, Bayer T, Read S: Dignity in Practice: An exploration 476 
of the care of older adults in acute NHS Trusts. In NIHR SDO reports. London: Her Majesty's 477 
Stationery Office; 2011. 478 
3. Miani C, Ball, S., Pitchforth, E., Exley, J., King, S. & Roland, M., Fuld, J., & Nolte, E. : 479 
Organisational interventions to reduce length of stay in hospital: a rapid evidence 480 
assessment. Health Services and Research Delivery 2014, 2. 481 
4. The Royal College of Psychiatrists: Who Cares Wins. London: The Royal College of 482 
Psychiatrists; 2005. 483 
5. Campbell SE, Seymour DG, Primrose WR, Project A: A systematic literature review of factors 484 
affecting outcome in older medical patients admitted to hospital. Age and Ageing 2004, 485 
33:110-115. 486 
6. Royal College of Physicians: Hospitals on the edge? The time for action. London: Royal 487 
College of Physicians of London; 2012. 488 
7. NICE: Emergency and acute medical care in over 16s: service delivery and organisation - 489 
Chapter 23 Liaison Psychiatry. London: NICE; 2017. 490 
8. Desan PH, Zimbrean PC, Weinstein AJ, Bozzo JE, Sledge WH: Proactive psychiatric 491 
consultation services reduce length of stay for admissions to an inpatient medical team. 492 
Psychosomatics 2011, 52:513-520. 493 
9. Sledge W, Gueorguieva R, Desan P, Bozzo J, Dorset J, Lee HB: Multidisciplinary Proactive 494 
Psychiatric Consultation Service: Impact on Length of Stay for Medical Inpatients 495 
Psychosomatics and Psychotherapy 2015, 84:208-216. 496 
22 
 
10. Nasreddine ZS, Phillips NA, Bédirian V, Charbonneau S, Whitehead V, Collin I, Cummings JL, 497 
Chertkow H: The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild 498 
cognitive impairment. Journal of the American Geriatrics Society 2005, 53:695-699. 499 
11. Wade D, Collin C: The Barthel ADL Index: a standard measure of physical disability? 500 
International disability studies 1988, 10:64-67. 501 
12. EuroQol G: EuroQol--a new facility for the measurement of health-related quality of life. 502 
Health Policy 1990, 16:199-208. 503 
13. Kroenke K, Spitzer RL, Williams JB, Löwe B: An ultra-brief screening scale for anxiety and 504 
depression: the PHQ–4. Psychosomatics 2009, 50:613-621. 505 
14. NICE: Methodology checklist: economic evaluations In The social care guidance manual. 506 
NICE; 2013. 507 
15. Claxton K, Martin S, Soares M, Rice N, Spackman E, Hinder S, Devlin N, Smith PC, Sculpher M: 508 
Methods for the estimation of the NICE cost-effectiveness threshhold. Health Technology 509 
Assessment 2015, 19. 510 
16. Barber J, Thompson S: Multiple regression of cost data: use of generalised linear models. 511 
Journal of Health Services Research & Policy 2004, 9:197-204. 512 
17. White IR, Royston P, Wood AM: Multiple imputation using chained equations: issues and 513 
guidance for practice. Statistics in medicine 2011, 30:377-399. 514 
18. Fenwick E, Claxton K, Sculpher M: Representing uncertainty: the role of cost‐effectiveness 515 
acceptability curves. Health economics 2001, 10:779-787. 516 
19. Briggs AH, Claxton K, Sculpher MJ: Decision modelling for health economic evaluation. 517 
Oxford University Press, USA; 2006. 518 
20. Drummond MF, Sculpher MJ, Torrance GW, O'Brien BJ, Stoddart GL: Methods for the 519 
economic evaluation of health care programmes. 3rd edn. Oxford, UK: Oxford University 520 
Press; 2005. 521 
 522 
23 
 
Figure 1.  The HOME Study: Schedule of enrolment, interventions, and assessments. 523 
 524 
 
Pre-
allocation 
Allocation 1 month 
(30 days) 
3 months 
(90 days) 
1 year 
Enrolment      
Eligibility screen x     
Informed consent x     
Randomisation  x    
Interventions      
Usual care  x-------------- x   
Usual care plus PLP/PPM  x-------------- x   
Assessments      
Number of days in hospital    x   
Cognitive function (MOCA-T)   x x  
Independent functioning (Barthel)   x x  
Health related quality of life (EQ-5D-5L)   x x  
Depression & anxiety symptoms (PHQ-4)   x x  
Overall quality of life (study-specific item)   x x  
Experience of hospital stay (study-specific item)   x   
View on length of hospital stay (study-specific item)   x   
Discharge destination   x x x 
Secondary healthcare use      x 
Death    x x x 
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